- Home
- CUBI vs AAPG Comparison
CUBI vs AAPG Comparison
Compare CUBI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUBI | AAPG |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | China |
| Employees | 790 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CUBI | AAPG |
|---|---|---|
| Price | $66.24 | $22.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $86.63 | $48.40 |
| AVG Volume (30 Days) | ★ 357.6K | 1.6K |
| Earning Date | 04-23-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.24 | N/A |
| Revenue Next Year | $9.30 | $368.64 |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.75 | $17.56 |
| 52 Week High | $82.56 | $48.45 |
Technical Indicators
Market Signals| Indicator | CUBI | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 37.58 |
| Support Level | $64.71 | $21.20 |
| Resistance Level | $68.28 | $25.47 |
| Average True Range (ATR) | 2.37 | 0.74 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 32.53 | 20.44 |
Price Performance
Historical ComparisonAbout CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.